The Advisory outlines the principles and components of low barrier care, and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

This Advisory, TIP 47, Substance Abuse: Clinical Issues in Intensive Outpatient Treatment, provides an overview of intensive outpatient (IOP) treatment. It discusses typical program goals; outlines key features that improve engagement, retention, and outcomes; and provides additional resources on this critical topic.

This Advisory, based on Treatment Improvement Protocol (TIP) 54, Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders, is for primary care providers who treat or are likely to treat adult patients with or in recovery from substance use disorders (SUDs) who present with chronic pain. It addresses screening and assessment tools, nonpharmacologic and nonopioid treatment for chronic pain, and the role of opioid therapy in people with chronic noncancer pain and SUDs.

This Advisory is based on Technical Assistance Publication (TAP) 21-A, Competencies for Substance Abuse Treatment Clinical Supervisors. It identifies foundational knowledge and concepts essential for supervisory proficiency, roles and skills expected of clinical supervisors, the purpose and context of competencies for supervision in substance use disorder (SUD) treatment programs, and dissemination and implementation of these competencies.

This Advisory is based on TIP 27, Comprehensive Case Management for Substance Abuse Treatment. It surveys the underlying principles and models of case management, discusses reasons substance use disorder (SUD) treatment providers might consider implementing or expanding the use of case management, and lists some case management-related resources and tools.

This Advisory is based on TIP 53, Addressing Viral Hepatitis in People with Substance Use Disorders. It offers guidance to providers and administrators in substance use disorder treatment programs on screening for, and treating clients with, hepatitis A, hepatitis B, and hepatitis C infections.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.